The company
Merck & Company, Inc. Common Stock (new)
MRK · NYSE
Health CarePharmaceuticalsLeading
MRK stood above a rising 150-day average in 49 of the last 52 weekly readings, including each of the last 49 weeks. It is 11.9% above that average now. Pharmaceuticals: 32% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Leading
- Weeks in an uptrend
- 49 in a row
- Industry in uptrend
- 32% -7 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $142.7M
- Officials’ trades on record
- 256
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 49 of 52 weeks.
20 Apr – 19 Oct
Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
1 Nov 2024 – 1 Oct 2026
Open-market buys above the line and sales below, in dollars. Not yet read: institutions.
Congress and officials
256 disclosed lines: House 173, Senate 66, executive 17; 72 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Maria Elvira Salazar House: U.S. House ClerkFL27 | sold | $1k–$15k | 24 Sep 2026filed 7 Oct 2026 |
| Maria Elvira Salazar House: U.S. House ClerkFL27 | bought | $15k–$50k | 19 Aug 2026filed 9 Sep 2026 |
| Maria Elvira Salazar House: U.S. House ClerkFL27 | bought | $15k–$50k | 19 Aug 2026filed 9 Sep 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $250k–$500k | 31 Jul 2026filed 22 Sep 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 23 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $50k–$100k | 15 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $50k–$100k | 12 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 18 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $15k–$50k | 15 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $15k–$50k | 5 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $50k–$100k | 27 Apr 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $15k–$50k | 27 Apr 2026filed 1 Jul 2026 |
Insiders
Buy orders, 12 months0
Sale orders, 12 months23
Buyers · sellers0 · 11
| Who | Did | Shares | Traded |
|---|---|---|---|
| Chirfi GuindoEVP, Access, Policy & Comms | sold | 10,000at $135.00 | 13 Aug 2026filed 13 Aug 2026 |
| Richard R. DelucaEVP&Pres, Merck Animal Heallth | sold | 11,099at $131.61 | 12 Aug 2026filed 12 Aug 2026 |
| Richard R. DelucaEVP&Pres, Merck Animal Heallth | sold | 600at $132.04 | 12 Aug 2026filed 12 Aug 2026 |
| Jennifer ZacharyEVP, General Counsel | sold | 80,315at $133.46 | 12 Aug 2026filed 13 Aug 2026 |
| Richard R. DelucaEVP&Pres, Merck Animal Heallth | sold | 7,410at $131.33 | 11 Aug 2026filed 12 Aug 2026 |
| Richard R. DelucaEVP&Pres, Merck Animal Heallth | sold | 5,427at $132.35 | 11 Aug 2026filed 12 Aug 2026 |
| Richard R. DelucaEVP&Pres, Merck Animal Heallth | sold | 20,784at $130.43 | 10 Aug 2026filed 12 Aug 2026 |
| Chirfi GuindoEVP, Access, Policy & Comms | sold | 15,000at $131.00 | 6 Aug 2026filed 7 Aug 2026 |
| Richard R. DelucaEVP&Pres, Merck Animal Heallth | sold | 805at $131.02 | 6 Aug 2026filed 10 Aug 2026 |
| Richard R. DelucaEVP&Pres, Merck Animal Heallth | sold | 4,945at $130.23 | 6 Aug 2026filed 10 Aug 2026 |
| Richard R. DelucaEVP&Pres, Merck Animal Heallth | sold | 300at $131.02 | 6 Aug 2026filed 10 Aug 2026 |
| David Michael WilliamsEVP, Chief Info&Digital Officer | sold | 4,600at $128.77 | 5 Aug 2026filed 7 Aug 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Still reading this part; it fills in a moment.
News
Merck's 2.4% Dividend Yield: A Reliable Income Stream or a Risky Bet on Recovery?insidermonkey.com · 19 Oct 2026AbbVie vs. Merck: Which Pharma Stock Offers Better Value?insidermonkey.com · 16 Oct 2026Merck's Rally Reflects Renewed Confidence, but Has the Market Priced in Too Much?insidermonkey.com · 16 Oct 2026Merck (MRK) Reports a Negative Operating Margin and Pays Out 266% of Earnings. What Explains Both?insidermonkey.com · 13 Oct 2026Merck worker alleges pregnancy news triggered three-year campaign to force her outhcamag.com · 12 Oct 2026Jefferies cuts Merck's remigromig sales forecast after eye-disease trial raises concernsproactiveinvestors.com · 12 Oct 2026Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug databiopharmadive.com · 12 Oct 2026Masterson recognized by Merck and AABP - High Plains Journalhpj.com · 8 Oct 2026
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.